Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 11, 2006, Pages 3801-3808

  Colombo, Sara ^a   Buclin, Thierry ^a   Cavassini, Matthias ^a   Décosterd, Laurent A ^a   Telenti, Amalio ^a   Biollaz, Jérôme ^a   Csajka, Chantal ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DIDANOSINE; EFAVIRENZ; ENZYME INDUCING AGENT; ESOMEPRAZOLE; FUSION INHIBITOR T20; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BAYES THEOREM; COHORT ANALYSIS; COVARIANCE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACOKINETICS; POPULATION PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; STEADY STATE;

ADULT; AGED; ALGORITHMS; AREA UNDER CURVE; BAYES THEOREM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OLIGOPEPTIDES; POPULATION; PYRIDINES; REPRODUCIBILITY OF RESULTS; RITONAVIR; TREATMENT OUTCOME;

EID: 33750597597     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00098-06     Document Type: Article

References (28)

1. Akaike, H. 1974. A new look at the statistical model identification. IEEE Trans. Automat. Control 19:716-723.
2. Barrios, A., A. L. Rendon, O. Gallego, L. Martin-Carbonero, L. Valer, P. Rios, I. Maida, T. Garcia-Benayas, I. Jimenez-Nacher, J. Gonzalez-Lahoz, and V. Soriano. 2004. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin. Trials 5:201-205.
3. Beal, S. 1994. Validation of a population model. NONMEM UsersNet Archive, University of California San Francisco, San Francisco, Calif. [Online.] http://www.phor.com/nonmem/nmo/topic006.html.
4. Bristol Myers Squibb Company. 2003. Investigator brochure atazanavir BMS-232632. Bristol Myers Squibb Company, Baar, Switzerland.
5. Bristol Myers Squibb Company. 2005. Reyataz (atazanavir sulfate) capsules: prescribing information. [Online.] http://www.bms.com.
6. Bristol Myers Squibb Company. 2005. Reyataz: European public assessment report (EPAR). Scientific discussion. [Online.] http://www.emea.eu.int /humandocs/Humans/EPAR/reyataz/reyataz.htm.
7. Colombo, S., T. Buclin, C. Franc, N. Guignard, M. Kbonkarly, P. Tarr, B. Rochat, J. Biollaz, A. Telenti, L. Decosterd, and M. Cavassini. 2006. Ritonavir boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposure. Antivir. Ther. 11:53-62.
8. Colombo, S., N. Guignard, C. Marzolini, A. Telenti, J. Biollaz, and L. A. Decosterd. 2004. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B 810:25-34.
9. Colonno, R. J., A. Thiry, K. Limoli, and N. Parkin. 2003. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob. Agents Chemother. 47:1324-1333.
10. de Maat, M. M., G. C. Ekhart, A. D. Huitema, C. H. Koks, J. W. Mulder, and J. H. Beijnen. 2003. Drug interactions between antiretroviral drugs and comedicated agents. Clin. Pharmacokinet. 42:223-282.
11. European Medicines Agency. 2005. EMEA public statement. Important new pharmacokinetic data demonstrating that REYATAZ (atazanavir sulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered. [Online.] http://www.emea.eu.int/pdfs/human/press /pus/20264904en.pdf.
12. Food and Drug Administration. 2003. Atazanavir medical review, application number 21-567. Food and Drug Administration, Washington, D.C.
13. Goldsmith, D. R., and C. M. Perry. 2003 Atazanavir. Drugs 63:1679-1693.
14. Hastie, T., and R. J. Tibshirani. 1990. Generalized additive models. Chapman and Hall, New York, N.Y.
15. Le, T. C., A. Barrail, C. Goujard, and A. M. Taburet 2005. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44:1035-1050.
16. Mandema, J. W., D. Verotta, and L. B. Sheiner. 1992. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharm. 20:511-528.
17. NONMEM Project Group. 1992. NONMEM users guides. NONMEM UsersNet, University of California San Francisco, San Francisco, Calif.
18. Perloff, E. S., S. X. Duan, P. R. Skolnik, D. J. Greenblatt, and L. L. von Moltke. 2005. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab. Dispos. 33:764-770.
19. Piliero, P. J. 2002. Atazanavir: a novel HIV-1 protease inhibitor. Expert Opin. Investig. Drugs 11:1295-1301.
20. Ray, J. E., D. Marriott, M. T. Bloch, and A. J. McLachlan. 2005. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br. J. Clin. Pharmacol. 60:291-299.
21. Rotger, M., P. Taffe, G. Bleiber, H. F. Gunthard, H. Furrer, P. Vernazza, H. Drechsler, E. Bernasconi, M. Rickenbach, and A. Telenti. 2005. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:1381-1386.
22. Sanne, I., P. Piliero, K. Squires, A. Thiry, S. Schnittman, and the Clinical Trial Group. 2003. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J. Acquir. Immune Defic. Syndr. 32:18-29.
23. Sheiner, L. B., S. Beal, B. Rosenberg, and V. V. Marathe. 1979. Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther. 26:294-305.
24. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
25. Taburet, A.-M., C. Piketty, C. Chazallon, L. Vincent, L. Gérard, V. Calvez, F. Clavel, J.-P. Aboulker, P.-M. Girard, and the ANRS Protocol 107 Puzzle 2 Investigators. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096.
26. Vora, S., A. G. Marcelin, H. F. Gunthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Peytavin, V. Calvez, L. Perrin, and S. Yerly. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20:35-40.
27. Winston, A., M. Bloch, A. Carr, J. Amin, P. W. Mallon, J. Ray, D. Marriott, D. A. Cooper, and S. Emery. 2005. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J. Antimicrob. Chemother. 56:380-387.
28. Zhang, D., T. J. Chando, D. W. Everett, C. J. Patten, S. S. Dehal, and W. G. Humphreys. 2005. In vitro inhibition of UDP-glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33:1729-1739.